MAMurray John Adams

Murray John Adams

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Murray John Adams has a total of 154 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Hemostasis in Exercise and the Athlete Part II, Plus An Additional Mini-Compilation

    by Murray J. Adams, Emmanuel J. Favaloro, Brendan R. Scott

  • Open Access

    Optimized Flow Cytometric Detection of Transient Receptor Potential Vanilloid-1 (TRPV1) in Human Hematological Malignancies

    by Sofia A Omari, Dominic P Geraghty, Alhossain A Khalafallah, Pooja Venkat, Yvette M Shegog, Scott J Ragg, Charles E. de Bock, Murray J Adams

    The ectopic overexpression of transient receptor potential vanilloid-1 (TRPV1) has been detected in numerous solid cancers including breast, prostate, pancreatic, and tongue epithelium cancer. However, the expression of TRPV1 in hematological malignancies remains unknown. Here we show through in silico analysis that elevated TRPV1 mRNA expression occurs in a range of hematological malignancies and present an optimized flow cytometry method to rapidly assess TRPV1 protein expression for both cell lines and primary patient samples. Three anti-TRPV1 antibodies were evaluated for intracellular TRPV1 detection using flow cytometry resulting in an optimized protocol for the evaluation of TRPV1 in hematological malignant cell lines and patients’ peripheral blood mononuclear cells (PBMC). Overexpression of TRPV1 was observed in THP-1 (acute monocytic leukemia) and U266B1 (multiple myeloma, MM), but not U937 (histiocytic lymphoma) compared to healthy PBMC. TRPV1 was also detected in all 49 patients (including B-cell non-Hodgkin’s lymphoma (B-NHL), MM and others, and 20 healthy controls. TRPV1 expression was increased in 8% of patients (MM=2, B-NHL=2). In conclusion, we provide an optimized flow cytometry method for routine expression analysis of clinical samples and show that TRPV1 is increased in 8% of patients with hematological malignancies.

  • Shedding of soluble glycoprotein VI is neither affected by animal-derived antibeta-2-glycoprotein 1 antibodies nor IgG fractions from patients with systemic lupus erythematosus

    by Yik C. Ho, Kiran D.K. Ahuja, Robert K. Andrews, Murray J. Adams

    Antibeta-2-glycoprotein 1 (antiβ2GP1) antibodies are associated with increased risk of thrombosis in patients with systemic lupus erythematosus (SLE). The specific effect(s) of antiβ2GP1 antibodies on platelets are unclear. Platelet activation in response to antiplatelet antibodies has been shown to induce shedding of the ectodomain of the platelet collagen receptor, glycoprotein VI (GPVI), releasing soluble GPVI (sGPVI). The aim of this study was to therefore determine whether antiβ2GP1 antibodies, and/or purified IgG fractions, from patients with SLE shed sGPVI from platelets. We determined sGPVI levels in platelet poor plasma from SLE patients with/without antiβ2GP1 antibodies (n = 37), as well as in platelet-rich plasma from healthy donors treated with either SLE-derived IgG fractions containing antiβ2GP1, animal-derived antiβ2GP1, or isotype control antibodies. Levels of sGPVI were higher in three SLE-derived platelet poor plasma with antiβ2GP1 antibodies (103.52 ± 12.32 ng/ml) compared with those without (28.11 ± 12.73 ng/ml). Neither SLE-derived IgG fractions containing antiβ2GP1 antibodies, nor animal-derived antiβ2GP1 antibodies induced significant shedding of sGPVI from healthy donor platelets compared with isotype controls. These results suggest that antiβ2GP1 antibodies do not affect shedding of sGPVI, and therefore collagen-mediated platelet signalling pathways. The shedding activity in SLE patients may be due to factors other than antiβ2GP1 antibodies, for example, metalloproteinases.


  • International Society on Thrombosis and Haemostasis core curriculum project: Core competencies in laboratory thrombosis and hemostasis

    by Karen A. Moffat, Verena Kiencke, Alicia N. Blanco, Claire McLintock, Flora Peyvandi, Moniek P. M. de Maat, Murray J. Adams, Pantep Angchaisuksiri, Sukesh Nair, Hiroko Tsuda, et al.


  • Deep vein thrombosis in a well-trained masters cyclist, is popliteal vein entrapment syndrome to blame?

    by Jack Kean, Ashleigh Pearton, James W. Fell, Murray J. Adams, Cecilia M. Kitic, Sam S. X. Wu, Stephen Stone, Emma K. Zadow

    Whilst athletes are the epitome of health, venous thromboembolisms (VTE) including deep vein thrombosis and pulmonary embolism have been demonstrated to occur in well-trained athletes. VTE is frequently misdiagnosed and poorly treated within this population, often resulting in career or life-threatening ramifications. Furthermore, VTE risk rises with increasing age (> 40 years), potentially affecting masters athletes. A 44-year-old well-trained male cyclist volunteered to participate in a research project investigating the influence of exercise on haemostasis in well-trained athletes. The cyclist presented with elevated d-Dimer levels both pre- (2251 ng/mL) and post-exercise (2653 ng/mL). The cyclist reported constant mild-pain in the left mid-calf region, with a cold tingling sensation in their left foot. Diagnosis of DVT was confirmed via a DVT squeeze test and Doppler ultrasound, with the clot located in the left popliteal vein. During the research project, the cyclist was exposed to numerous thrombogenic risk factors including travel, dehydration, prolonged sitting and exercise. The DVT in the popliteal vein may have resulted from repetitive movements associated with cycling. Additionally, hypertrophy of the gastrocnemius muscle may have impinged the vein. When diagnosing DVT within a cycling population, PVES should not be overlooked as a contributing factor.


  • Hemostasis in Exercise and the Athlete

    by James W. Fell, Murray J. Adams

    We are thrilled to bring you this cross-disciplinary special issue of Seminars in Thrombosis and Hemostasis. This issue focuses on two specific aspects of hemostasis and exercise: (1) how exercise affects the hemostatic system in healthy individuals, including professional and well-trained athletes, and (2) the effects of exercise on patient groups with hemostatic abnormalities, including thrombotic and bleeding disorders, in improving overall health and lifestyle. Paradoxically, the issue's focus on healthy and trained athletes explores the risks of hemostasis associated with exercise, while for patient groups, it is the benefits of exercise that unites the authors in this issue, with constructive recommendations for promoting exercise participation in these groups. It is well known that physical activity is beneficial for health and can lower the risk of cardiovascular disease[1] [2] [3]; however, vigorous exercise is associated with thromboembolic and sudden cardiac events, particularly in untrained individuals. Exploring the concept of transitioning from risk to benefit, in the first review of this issue (by van der Vorm et al),[4] the authors provide an overview of existing literature on how training programs and training status influence hemostasis in healthy individuals. Furthermore, pilot study data are presented describing the effects of repetitive submaximal intensity cycling on procoagulant and anticoagulant processes in physically fit individuals. This is followed by a series of chapters focusing on hemostatic issues in well-trained or professional athletes. Traditional “at-risk” groups such as those with malignancy, genetic, and acquired risk factors are often at risk due to one or more contributing factors identified from Virchow's triad.[5] Similarly, athletes are also exposed to various training, competition, and career-related challenges that might contribute to the risk factors identified by Virchow.[5] Zadow et al initially reviews the acquired thrombotic risk factors that are specific to the athlete.[6] Various repetitive forms of exercise, dehydration, and prolonged travel, especially in combination, represent significant athlete-dependent risk factors to athletes, particularly in the development of venous thromboembolism (VTE). Anabolic androgenic steroid (AAS) use is suggested by Zadow et al[6] as one of the risk factors for athletes, so it is fitting that the next review by Chang et al[7] critiques the potential associations between AAS abuse and risk of thrombosis. The side effects of AAS are well described[8] [9] [10]; however, there are limited studies that describe the effects on the hemostatic system by these agents. From those studies that have been published, there is evidence to suggest that AAS abuse is associated with a significant risk of thrombosis, although improvements in study design to establish a clear causal relationship between AAS abuse and risk of thrombosis are required. How future prospective studies are designed, particularly in consideration of human ethics, to further explore these affects will be challenging. The first full original study in this issue (by Lippi et al)[11] investigated the acute effects of middle-distance endurance running (half-marathon: 21.1 km) on blood coagulation parameters in 33 middle-aged male athletes. The study investigated changes to hemostasis before, immediately after the run, and 3 hours after run completion. Several prothrombotic changes in blood coagulation markers were observed after the run, including increases in prothrombin time, D-dimer, von Willebrand factor antigen, and factor VIII (FVIII), as well as a significant reduction in the activated partial thromboplastin time. These changes implicate an increased risk of thrombotic events in participants undertaking a half marathon. Following on from the study of the effects of running on hemostasis, the next review by Kupchak[12] explores more deeply another factor that may impact on the risk of thrombosis in athletes, air travel. Exercise[13] [14] [15] and air travel[16] [17] have independently been shown to increase the risk of thrombosis; however, few studies have investigated these in combination. The amount of air travel undertaken by competitive athletes, including long-haul flights (> 6 hours duration), have risen considerably in the last few decades, alongside increasing reports in the popular press of VTE occurring in athletes. The combination of exercise and air travel along with other risk factors such as dehydration, repetitive trauma, and injury, compounded by other factors such as use of oral contraceptives in females, or hereditary thrombophilia, may be a considerable contributing factor to VTE occurrence in a small number of susceptible athletes who regularly travel to train or compete.[12] [16] [17] In contrast to the potential risk presented for higher trained competitive athletes, Evensen et al[18] review the effects of regular physical activity on overall risk of VTE and VTE-related complications. Despite a considerable amount of published research, the authors suggest that a clear association between physical activity and risk of incident VTE has yet to be thoroughly established, with evidence suggesting that physical activity has a beneficial effect on the risk of VTE, but not in a dose-dependent manner. The authors suggest that this may be due to methodological challenges related to research on physical activity, such as standardized assessment of physical activity, and sources of bias in previous studies, but also raises the question as to whether higher levels of training undertaken by elite and professional athletes may be an additional thrombotic risk factor not often considered. Beyond a focus on the risk of VTE in athletic populations, the general consensus is that physical activity should be promoted for maintenance of health and disease; however, the risk of adverse events such as sudden death still...


  • Acquired and Genetic Thrombotic Risk Factors in the Athlete

    by Murray John Adams, Cecilia M. Kitic, Sam Shi Xuan Wu, James William Fell, Emma Kate Zadow

    While athletes are often considered the epitome of health due to their physique and lowered potential for metabolic and cardiovascular diseases, they may also be at risk for the onset and development of venous thromboembolism (VTE). In an attempt to achieve and remain competitive, athletes are frequently exposed to numerous athlete-specific risk factors, which may predispose them to VTE through the disruption of factors associated with Virchow's triad (i.e., hypercoagulability, venous stasis, and vessel wall injury). Indeed, hypercoagulability within an athletic population has been well documented to occur due to a combination of multiple factors including exercise, dehydration, and polycythemia. Furthermore, venous stasis within an athletic population may occur as a direct result of prolonged periods of immobilization experienced when undertaking long-distance travels for training and competition, recovery from injury, and overdevelopment of musculature. While all components of Virchow's triad are disrupted, injury to the vessel wall has emerged as the most important factor contributing to thrombosis formation within an athletic population, due to its ability to influence multiple hemostatic mechanisms. Vessel wall injury within an athletic population is often related to repetitive microtrauma to the venous and arterial walls as a direct result of sport-dependent trauma, in addition to high metabolic rates and repetitive blood monitoring. Although disturbances to Virchow's triad may not be detrimental to most individuals, approximately 1 in 1,000 athletes will experience a potentially fatal post-exercise thrombotic incidence. When acquired factors are considered in conjunction with genetic predispositions to hypercoagulability present in some athletes, an overall increased risk for VTE is present.


  • Crossmatching Maternal and Fetal Blood in Sheep

    by Gabrielle C Musk, Murray J Adams, Haruo Usuda, Matthew W Kemp, Claire R Sharp

    We investigated the incidence of ex vivo incompatibility between ovine maternal RBC and fetal plasma. Time-mated singleton pregnant ewes (n = 8) underwent cesarean delivery of the fetus; at the time of delivery, paired maternal and fetal blood samples were collected and subsequently separated for storage as packed RBC and fresh frozen plasma. Gel column crossmatching was performed 3 to 4 wk later. All fetus–dam crossmatches were considered major crossmatches, combining fetal (recipient) plasma with dam (donor) RBC. The plasma of 8 fetuses was cross-matched with RBC from 5 dams; all autologous controls were negative, and all but one crossmatch (1 of 40, 2.5%) were considered compatible. In addition, the plasma of 3 dams was crossmatched with RBC from 5 dams; all autologous controls were negative; however, significant incompatibility was noted. In total, 4 of 13 (30.8%) dam–dam crossmatches were considered incompatible. The results of this initial study suggest that when a single animal receives multiple blood-product transfusions, the risk of an immunologic transfusion reaction can be reduced by ensuring that the blood products are obtained from a single donor, performing a crossmatch prior to transfusion, and the use of synthetic products to increase the oxygen carrying capacity of fetal blood.


  • Compression socks and the effects on coagulation and fibrinolytic activation during marathon running

    by E. K. Zadow, M. J. Adams, S. S. X. Wu, C. M. Kitic, I. Singh, A. Kundur, N. Bost, A. N. B. Johnston, J. Crilly, A. C. Bulmer, et al.

    Compression socks are frequently used in the treatment and prevention of lower-limb pathologies; however, when combined with endurance-based exercise, the impact of compression socks on haemostatic activation remains unclear.


  • Synergistic inhibitory effect of capsaicin and dihydrocapsaicin on in-vitro platelet aggregation and thromboxane formation

    by Safa Almaghrabi, Murray Adams, Dominic Geraghty, Kiran Ahuja

    Capsaicinoids, including capsaicin (CAP) and dihydrocapsaicin (DHC), the pungent principles of pepper fruits, individually inhibit in-vitro platelet aggregation. However, their effects, when present together, are not known. The aims of this study were to compare the effects of CAP and DHC alone, and in combination in the ratio that they are found in chilies (∼60% CAP : 40% DHC), on in-vitro platelet aggregation, platelet count and thromboxane B2 (TXB2) formation. The effects of 12.5 and 6.25 μmol/l CAP and DHC individually, and in combination (CAP : DHC, 60 : 40) on arachidonic acid-induced, ADP-induced and collagen-induced aggregation, were investigated. Platelet count was determined preincubation and postincubation with CAP and DHC and in combination. TXB2 formation from platelets treated with arachidonic acid in the absence and presence of CAP and DHC individually, and in combination, was measured. Compared with control, CAP and DHC (12.5 μmol/l) inhibited arachidonic acid-induced aggregation by 23.2 and 25.3%, respectively (both P < 0.01). In combination, CAP and DHC exhibited further inhibition in arachidonic acid-induced aggregation (CAP : DHC, 3.75 : 2.5 μmol/l, 36.5%, P = 0.01; 7.5 : 5 μmol/l, 57.5%, P < 0.001), compared with control. Incubation of platelets with caspaicinoids did not significantly affect the platelet count. In addition, the CAP : DHC (7.5 : 5 μmol/l) combination significantly inhibited (P < 0.001) TXB2 formation, compared with the individual capsaicinoids. Capsaicinoids had no effect ADP-induced or collagen-induced aggregation. The combination of CAP and DHC produces a significantly greater inhibitory effect on arachidonic acid-induced platelet aggregation and subsequent TXB2 formation, compared with the individual capsaicinoids.